

1 **Development and Performance Assessment of a Novel Plasma p-Tau181 Assay**
2 **Reflecting Tau Tangle Pathology in Alzheimer's Disease**

3

4 **AUTHORS/AFFILIATIONS:**

5 Kenji Tagai^{1,2,7}, Harutsugu Tatebe^{1,7}, Sayo Matsuura¹, Zhang Hong¹, Naomi Kokubo¹,
6 Kiwamu Matsuoka¹, Hironobu Endo¹, Asaka Oyama¹, Kosei Hirata¹, Hitoshi Shinotoh¹,
7 Yuko Kataoka¹, Hideki Matsumoto^{1,3}, Masaki Oya¹, Shin Kurose^{1,4}, Keisuke
8 Takahata^{1,4}, Masanori Ichihashi¹, Manabu Kubota¹, Chie Seki¹, Hitoshi Shimada^{1,5},
9 Yuhei Takado¹, Kazunori Kawamura¹, Ming-Rong Zhang¹, Yoshiyuki Soeda⁶, Akihiko
10 Takashima⁵, Makoto Higuchi¹, Takahiko Tokuda^{1*}

11

12 ¹ Institute for Quantum Medical Science, Quantum Life and Medical Science
13 Directorate, National Institutes for Quantum Science and Technology, Chiba 263-8555,
14 Japan

15 ² Department of Psychiatry, The Jikei University of Medicine, Tokyo 105-8461, Japan

16 ³ Department of Oral and Maxillofacial Radiology, Tokyo Dental College, Tokyo 101-
17 0061, Japan

18 ⁴ Department of Psychiatry, Keio University School of Medicine, Tokyo 160-0016,
19 Japan

20 ⁵ Department of Functional Neurology & Neurosurgery, Center for Integrated Human
21 Brain Science, Brain Research Institute, Niigata University, Niigata 951-8585, Japan

22 ⁶ Laboratory for Alzheimer's Disease, Department of Life Science, Faculty of Science,
23 Gakushuin University, Tokyo 171-8588, Japan

24 ⁷ These authors contributed equally

25 * Correspondence: tokuda.takahiko@qst.go.jp

26

27

1 **Abstract:** Several blood-based assays for phosphorylated tau (p-tau) have been
2 developed to detect brain tau pathologies in Alzheimer's disease (AD). However, plasma
3 p-tau measured by currently available assays is influenced by brain amyloid and,
4 therefore, could not accurately reflect brain tau deposits. Here, we devised a novel
5 immunoassay that can quantify N- and C-terminally truncated p-tau fragments (mid-p-
6 tau181) in human plasma. We measured plasma p-tau181 levels in 164 participants who
7 underwent both amyloid and tau positron emission tomography (PET) scans using mid-
8 p-tau181 and conventional p-tau181 assays. The mid-p-tau181 assay displayed stronger
9 correlations with tau PET accumulation than the conventional assay in the AD
10 continuum and accurately distinguished between tau PET-positive and -negative cases.
11 Furthermore, the mid-p-tau181 assay demonstrated a trajectory similar to tau PET
12 alongside cognitive decline. Consequently, our mid-p-tau181 assay could be useful in
13 evaluating the extent of brain tau burden in AD.

14
15 **Keywords:** Plasma biomarker, Tau phosphorylated at threonine 181 (p-tau181), Simoa,
16 Tau PET, Alzheimer's disease

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

1 **Introduction**

2 Estimates project that the number of people with dementia worldwide will reach
3 153 million by 2050¹, highlighting the urgent need to address the remarkable health and
4 social impacts of this condition. Alzheimer's disease (AD), the most prevalent form of
5 dementia, has been characterized as the deposit of two abnormal proteins, namely
6 amyloid- β (A β) and tau, in the brain. Over the years, numerous disease-modifying
7 therapies (DMTs) targeting these abnormal proteins have been developed², with the
8 Food and Drug Administration (FDA) having recently approved several DMTs targeting
9 A β due to their efficacy in decreasing brain amyloid deposition and modestly slowing
10 AD progression³⁻⁵. Researchers anticipate that these DMTs will be increasingly utilized
11 in clinical practice, with the potential for developing additional DMTs targeting not only
12 A β but also tau in the near future⁶.

13 Biomarkers have become an integral part of clinical trials on DMTs given their
14 widespread use for subject recruitment and outcome measurements². The
15 amyloid/tau/neurodegeneration (A/T/N) biomarker classification system had been
16 proposed for the biological staging of AD⁷. In particular, positron emission tomography
17 (PET) has emerged as a well-established imaging biomarker for assessing the
18 accumulation of A β and tau in the brain⁸, playing a critical role in evaluating novel
19 DMTs^{4,9}. The noteworthy decline in amyloid accumulation based on PET findings¹⁰
20 may have expedited the FDA approval of aducanumab². Moreover, incorporating tau
21 PET as a screening measure, assuming that high tau accumulation may cause resistance
22 to anti-amyloid therapy, may have played a part in the success of the donanemab
23 clinical trial^{4,11}. Despite their usefulness, PET scans are not ideal for frequent
24 assessment or large-scale screening given their limited availability, high cost, and
25 radiation exposure¹². Similarly, A β and p-tau in the cerebrospinal fluid (CSF) have also
26 been accepted as standard biomarkers for qualifying AD pathology^{13,14}. However, CSF
27 testing has seen somewhat limited use considering its invasiveness, low-throughput
28 nature, and need for expertise during CSF sampling^{12,15}. Based on the present
29 circumstances surrounding the development of biomarkers for AD, one of the most
30 critical unmet needs has been the identification of blood-based biomarkers closely
31 correlated with tau PET parameters that reflect brain tau burden, especially in the
32 context of selecting suitable patients for anti-amyloid therapies.

33 Recent advances in measurement methodologies have made it possible to quantify
34 minute amounts of proteins in the peripheral blood that are associated with brain
35 diseases, thereby enabling the feasibility of blood-based biomarkers¹⁵. Notably, there is
36 growing evidence for the clinical significance of plasma phosphorylated tau (p-tau)

1 assays in detecting AD pathology^{16–19}, similar to CSF biomarkers. The C-terminal
2 portion of the tau protein, which predominantly constitutes neurofibrillary tangles²⁰, is
3 seldom detectable in biofluids^{21–23}. Most of the current immunoassays for plasma p-tau,
4 therefore, employ a pair of antibodies, one of which recognizes the phosphorylated
5 residues, such as Thr181, Thr217, and Thr231, in the mid-portion, while the other
6 identifies the N-terminal region of the tau protein. Accordingly, currently available
7 immunoassays for plasma p-tau detect C-terminally truncated p-tau containing the N-
8 terminus to the mid-domain (N-p-tau)¹². Plasma p-tau levels quantified using these N-
9 p-tau assays can accurately differentiate between AD pathology and other tauopathies
10 with high diagnostic accuracy^{17,18,24,25} and help predict future cognitive decline from
11 prodromal phases^{26,27}. However, one of the significant problems in the clinical use of N-
12 p-tau assays is their inability to be considered as a surrogate marker for tau burden in
13 the brain²⁸ given that the measurements obtained had a more pronounced association
14 with amyloid PET than with tau PET^{29–32}. Therefore, the need for developing blood-
15 based tau biomarkers strongly correlated with PET-detectable tau accumulations in the
16 brain remains unmet.

17 The present study aimed to formulate a novel p-tau assay that can be
18 interchangeable with the tau PET study. Considering that the truncation of the N-
19 terminal of the tau protein may occur subsequent to the truncation of its C-terminal with
20 the formation of neurofibrillary tangle³³, we hypothesized that the levels of both N- and
21 C-terminally truncated p-tau181 fragments could be correlated with the abundance of
22 tau aggregates in the brain. Thus, we developed a novel mid-region-directed p-tau181
23 assay by modifying the formerly established N-p-tau181 assay¹⁶. To validate our
24 hypothesis, we collected plasma samples from subjects who underwent PET with both
25 ¹¹C-Pittsburgh Compound B (¹¹C-PiB) and ¹⁸F-florzorotau (aka PM-PBB3/APN-1607)
26 for the examination of A β and tau depositions in the brain, respectively.^{34,35} We
27 demonstrated a strong correlation of between plasma levels of p-tau181 fragments
28 measured using our mid-region-directed assay (hereinafter called mid-p-tau181) and tau
29 PET tracer retention but no linear correlation between plasma N-p-tau181 levels and tau
30 PET data, suggesting the clinical usefulness of the novel assay as a surrogate biomarker
31 for PET-visible tau pathologies.

32

33 **Results**

34 ***Validation of the newly developed mid-p-tau181 assay***

35 The plasma mid-p-tau181 assay exhibited high analytical performance (Supplementary
36 Methods and Results, Supplementary Tables 1–3, Supplementary Figures 1–5), with

1 high precision within and between runs. Spike recovery experiments and parallelism of
2 serially diluted plasma samples confirmed the reliability of the measurements.

3 4 ***Demographic data***

5 Table 1 summarizes the demographic information of the participants. All participants (n
6 = 164) underwent neuropsychological assessment, including the Clinical Dementia
7 Rating (CDR) scale, Mini-Mental State Examination (MMSE), and frontal assessment
8 battery (FAB), simultaneous amyloid and tau PET imaging, and blood sampling on the
9 day of the PET examination. Cognitively normal (CN) individuals exhibiting negative
10 results on amyloid and tau PET imaging were designated into the CN cohort. Patients
11 with mild cognitive impairment (MCI) and AD who had positive amyloid PET findings
12 were categorized into the AD continuum group (dubbed AD group). Furthermore,
13 subjects with progressive supranuclear palsy (PSP) and other frontotemporal lobar
14 degeneration (FTLD) who had negative amyloid PET findings were classified into the
15 PSP and FTLD cohorts, respectively. No significant differences in age, years of
16 schooling, and gender were observed among the groups. All patient groups showed
17 lower MMSE (CN, 29.3 ± 1.0 ; AD, 21.9 ± 4.1 ; PSP, 24.8 ± 5.8 ; FTLD, 23.8 ± 6.1) and
18 FAB scores (CN, 16.7 ± 1.2 ; AD, 13.0 ± 3.0 ; PSP, 12.0 ± 3.6 ; FTLD, 11.0 ± 4.8) than
19 the CN group ($p < 0.05$, Table 1). Notably, 90% of the AD group comprised subjects
20 with early-stage AD who had a CDR score of 0.5 or 1 accounted; however, the mean
21 MMSE scores of this group were lower than those of the PSP group ($p < 0.05$, Table 1)
22 but did not significantly differ from those of the FTLD group.

23 24 ***Significant linear correlation between plasma mid-p-tau181 but not N-p-tau181 with*** 25 ***tau PET findings in patients with AD continuum***

26 We found a significant linear correlation between the plasma mid-p-tau181 levels and
27 tau PET tracer retention in patients with AD continuum (Figure 1). Voxel-wise analyses
28 revealed a positive correlation between plasma mid-p-tau181 levels and tracer binding
29 in the temporal and parietal cortices [Figure 1A; $p < 0.05$, corrected for family-wise
30 error (FWE)]. This finding was corroborated by the following three different
31 quantitative indices based on a region of interest (ROI): (1) standardized uptake value
32 ratio (SUVR)³⁶ in the temporal meta-ROI that characterizes tau lesions in AD³⁷; (2) AD
33 tau score, which is a machine learning-based measure indicating AD-related features of
34 tau PET images³⁵; and (3) Braak staging SUVRs based on the neuropathological
35 hypothesis³⁶ (Supplementary Figure 6). These AD signature ROI analyses revealed
36 significant linear correlations between plasma mid-p-tau181 levels and temporal meta-

1 ROI SUVRs ($r = 0.506$; $p = 0.0003$), AD tau scores ($r = 0.556$; $p = 0.0003$), and SUVRs
2 in the Braak stage III/IV limbic ($r = 0.403$; $p = 0.003$) and V/VI neocortical ($r = 0.508$; p
3 $= 0.0003$) but not Braak stage I/II entorhinal ($r = 0.216$; $p = 0.149$) ROIs. These findings
4 clearly demonstrate that plasma mid-p-tau181 levels could accurately reflect AD-related
5 tau accumulation that spreads from the entorhinal cortex first to the inferior temporal
6 lobe and then to the parieto-occipital regions of the neocortex but not tau accumulation
7 in the Braak I/II region.

8 Conversely, the conventional N-p-tau181 assay (Simoa pTau-181 Advantage V2.1
9 kit, Quanterix, MA, USA) showed no significant linear correlations with tau PET tracer
10 retention (Figure 2). Voxel-based analysis revealed a weak correlation between these
11 plasma and imaging parameters in the temporal cortex (Figure 2A; $p < 0.05$,
12 uncorrected); however, no significant correlation was observed upon correction for
13 multiple comparisons ($p < 0.05$, FWE-corrected). Moreover, none of the three ROI-
14 based analyses revealed significant linear correlations between N-p-tau181 levels and
15 PET parameters ($p > 0.05$ after Bonferroni's correction; Figure 2B, C). Instead, these
16 examinations showed inverse U-shaped nonlinear correlations between plasma N-p-
17 tau181 levels and tau PET SUVRs in the temporal meta-ROI ($R^2 = 0.402$), AD tau score
18 ($R^2 = 0.147$), and Braak stage III/IV ($R^2 = 0.307$) and V/VI ROIs ($R^2 = 0.223$) but not
19 Braak stage I/II ROIs (Figure 2B, C).

20

21 ***Specific association of plasma mid-p-tau181 with tau PET measures of pathology*** 22 ***over amyloid PET measures***

23 Next, plasma p-tau181 levels determined by either the pre-established (N-p-tau181) or
24 newly developed (mid-p-tau181) assay was assessed for association with amyloid-PET
25 and tau-PET measures of pathology (Figure 3). The analysis included both AD and CN
26 groups to avoid the ceiling effect of amyloid PET accumulation that would be the case
27 when analyzing only the subjects with AD continuum. The results of the correlation
28 analysis showed that plasma mid-p-tau181 levels were more strongly associated with
29 tau PET accumulation than with amyloid, while plasma N-p-tau181 levels were more
30 strongly associated with amyloid PET accumulation than with tau (Figure 3A). Multiple
31 linear regression analysis also revealed that plasma mid-p-tau181 levels were
32 significantly influenced only by tau PET accumulation (Amyloid PET: $p = 0.056$; Tau
33 PET: $p < 0.0001$, Adjusted $R^2 = 0.450$). Meanwhile, plasma N-p-tau181 levels were
34 influenced by both amyloid and tau PET accumulation (Amyloid PET: $p = 0.002$; Tau
35 PET: $p = 0.020$, Adjusted $R^2 = 0.420$). (See Figure 3B and Supplementary Table 4)

36

1 ***Comparisons between the two plasma p-tau181 assays according to their correlation***
2 ***with structural imaging biomarkers***

3 The relationship of brain volume and cortical thickness, assessed by magnetic resonance
4 imaging (MRI), with measures of each p-tau181 assay was also examined. Voxel-based
5 morphometry revealed significant negative correlations between the plasma mid-p-
6 tau181 concentration and gray matter volume in the neocortex, primarily in the temporal
7 and parietal areas (Figure 4). The ROI-based analysis also confirmed a correlation
8 between mid-p-tau181 and cortical thinning in AD-signature regions defined as
9 described elsewhere³⁸ ($r = -0.406$; $p = 0.005$). In contrast, N-p-tau181 did not exhibit
10 any correlation with structural imaging measures.

11

12 ***Discriminating between tau PET statuses using plasma mid-p-tau181 levels***

13 Using three different ROI-based methods, we qualitatively assessed the PET-detectable
14 tau burden in the CN subjects and AD continuum patients. Thereafter, receiver operating
15 characteristic (ROC) curve analyses were conducted to determine plasma mid-p-tau181
16 cutoff levels for discriminating between individuals with positive and negative AD-type
17 tau PET findings. The PET finding classification was based on the cutoff values of
18 imaging-based Braak staging, temporal meta-ROI SUVR, and AD tau score. The Braak
19 stage in each subject was determined according to the ROI with the highest Z-score (see
20 Methods for detailed procedures), with stages 0 and I/II indicating tau-negative and
21 stages III/IV and V/VI being classified as tau-positive (Supplementary Table 5). The
22 cutoff values for the meta-ROI SUVR and AD tau score were determined using ROC
23 curve analyses in the current and previous studies³⁵, respectively (Supplementary Table
24 5). Consequently, our findings showed that tau-positive AD cases had significantly
25 higher plasma mid-p-tau181 concentrations than did tau-negative AD and CN cases
26 (Figure 5A; $p < 0.0001$). Furthermore, area under the ROC curve (AUC) values for the
27 mid-p-tau181-based differentiation between tau PET positivity and negativity defined
28 by all three methods exceeded 0.85 (Table 2, Figure 5B), indicating that this plasma
29 biomarker with reference to PET-based classifications had robust discriminative power.

30

31 ***Discriminating among diagnostic groups and between amyloid PET statuses using***
32 ***plasma biomarkers***

33 Supplementary Figure 7A illustrates group comparisons of four AD-related plasma
34 biomarkers, including the mid-p-tau181 measured using our in-house assay, and the
35 corresponding values for each diagnostic group being presented in Table 1. Our results
36 indicated significant differences in A β 42/40 and N-p-tau181 concentrations between the

1 AD and other groups. Additionally, the AD group exhibited significantly higher mid-p-
2 tau181 concentrations than did all other groups except the PSP group. Moreover, all
3 disease groups had increased neurofilament light chain (NfL) concentrations compared
4 to the CN group. ROC curve analyses (Supplementary Figure 7B) revealed the
5 following order of the biomarker performances for discriminating between individuals
6 with and without ¹¹C-PiB-PET-positive amyloid pathology when all participants were
7 incorporated: N-p-tau181 (AUC = 0.867), Aβ42/40 (AUC = 0.850), mid-p-tau181
8 (AUC = 0.771), and NfL (AUC = 0.555).

9
10 ***Trajectory analyses of imaging- and blood-based A/T/N biomarkers along with***
11 ***cognitive decline in the CN and AD continuum subjects***

12 The imaging biomarkers examined in this cohort revealed that the A marker (i.e.,
13 amyloid PET index) displayed a sigmoidal trajectory when plotted against cognitive
14 deficits and reached a plateau when the MMSE score was around 20 points, the point at
15 which cognitive decline became apparent (Figure 6A). Conversely, the T marker (i.e.,
16 tau PET index) displayed a linearly progressive increase with a decrease in the MMSE
17 scores. The N marker (i.e., the volumetric MRI index) also tended to show a linear
18 increment similar to that for the T marker, albeit with a lesser z-score range.

19 The blood-based biomarkers displayed trajectories closely resembling those of the
20 corresponding imaging biomarkers, although their dynamic ranges were inferior to
21 those of the imaging biomarkers (Figure 6B). Notably, the two different blood-based T
22 markers showed clearly distinct trajectories such that plasma mid-p-tau181 levels
23 exhibited a linearly progressive increase similar to the tau PET index with the decline in
24 MMSE scores, whereas plasma N-p-tau181 levels displayed a sigmoidal trajectory
25 similar to that for amyloid PET with the decrease in MMSE scores. The A (Aβ42/40)
26 and N (NfL) markers showed a sigmoidal curve and a linear progression, respectively,
27 similar to those for the corresponding imaging biomarkers.

28
29 **Discussion**

30 The current study aimed to develop a novel plasma p-tau biomarker, mid-p-tau181,
31 which could accurately reflect the AD-type tau burden in the brain assessed by tau PET,
32 and could thus be interchangeable with tau PET imaging. Notably, our results showed
33 that the plasma mid-p-tau181 exhibited a stronger association with tau PET than
34 amyloid PET in AD brains and was accordingly able to discriminate individuals
35 presenting positivity and negativity for PET-detectable AD tau pathologies. Amyloid
36 depositions in the brain have been known to affect the plasma levels of N-terminally

1 untruncated forms of p-tau181 (N-p-tau181) detected by most conventional p-tau
2 assays.^{17,26} By contrast, plasma mid-p-tau181 levels could have sufficient accuracy in
3 determining the existence of AD-type tau pathology without being affected by amyloid
4 accumulation. Moreover, the plasma mid-p-tau181 levels displayed a linear elevation
5 along with declines in MMSE scores, similar to tau PET measures. These results
6 strongly suggest the potential utility of plasma mid-p-tau181 as a blood-based
7 biomarker for detecting and staging tau pathologies from preclinical to advanced
8 clinical phases of the AD continuum.

9 Various non-clinical and clinical studies have suggested that an increase in soluble
10 p-tau in biofluids could be strongly associated with A β aggregation.^{17,29,30,39–42} This
11 evidence indicates that tau hyperphosphorylation occurs in neurons exposed to A β , with
12 p-tau levels increasing in response to A β deposition. Consistent with this notion, plasma
13 p-tau is highly valuable for distinguishing AD from other A β -negative
14 neurodegenerative diseases.^{18,43–45} In addition, concentrations of N-terminally intact p-
15 tau measured using conventional assays have been recognized as an early marker for
16 AD, given the increase in their values alongside A β deposition^{17,44,46–49} rather than PET-
17 visible tau aggregations.^{19,28,30} Meanwhile, tangle maturation also needs to be
18 considered when interpreting the levels of soluble p-tau in biofluids measured using
19 immunoassay methodologies. Most current approaches for quantifying soluble p-tau via
20 immunoassay predominantly target tau forms phosphorylated at positions 181, 217, or
21 231 and bearing N-terminal epitopes.¹² The C-terminal portion of the tau protein
22 involved in its aggregation⁵⁰ is rarely present in soluble tau species. Thus, soluble tau
23 species present in the body fluids usually include only the N-terminal-to-mid region
24 epitopes, ensuring consistent quantification using N-p-tau assays currently accessible.¹²
25 In the meantime, N-terminal and C-terminal cleavages occur in tau proteins
26 insolubilized and deposited in the brain, which has been postulated to play a role in
27 tangle evolution.^{33,51–53} Therefore, conventional plasma N-p-tau assays are likely to be
28 incapable of assessing N-terminally truncated tau species that can be elevated with the
29 advancement of tangle formations. Concurrent with this perspective, a study
30 investigating the associations between various plasma p-tau species and amyloid/tau
31 PET demonstrated that all plasma p-tau species measured by N-p-tau assays were more
32 tightly associated with amyloid-PET than tau-PET.³⁰ These findings support the notion
33 that currently available p-tau assays are not interchangeable with tau PET but can
34 provide surrogates for amyloid depositions.

35 Conversely, our mid-p-tau181 assay strongly correlated with tau but not amyloid
36 PET indices in AD brains. Since ¹⁸F-florzolotau, which was employed as a radioligand

1 for tau PET imaging here, exerts high sensitivity and specificity for tau versus amyloid
2 aggregates in the AD spectrum,³⁴ the plasma mid-p-tau181 measurement for the first
3 time offers the blood-based proper “T” biomarker in the ATN framework, corresponded
4 to the AD-type tau accumulation in tau PET scans.

5 Moreover, the characteristics of mid-p-tau181 suggest its usefulness as a biomarker
6 for predicting the therapeutic response to current DMTs targeting A β . These therapies
7 are more likely to be effective when introduced before substantial tau aggregation.

8 ^{2,11,54,55} Our results showed that our plasma mid-p-tau181 could discriminate between
9 tau-positive and -negative subjects with a specificity greater than 85%, and that plasma
10 mid-p-tau levels showed a significant linear correlation with tau PET tracer retention in
11 patients with AD continuum. Therefore, reasonable estimation of brain tau accumulation
12 by using plasma levels of mid-p-tau181 could identify patients with high plasma mid-p-
13 tau levels, in whom brain tau aggregation has been suggested to have progressed
14 beyond the critical point, and could thereby help select patients with low-to-moderate
15 tau burden who are more likely to benefit from DMTs targeting A β , like so in the phase
16 3 study of donanemab.¹¹

17 Plasma mid-p-tau181 levels were also correlated with brain atrophy and increased
18 with the progression of cognitive impairment evaluated using MMSE scores in the
19 trajectory analysis. Meanwhile, plasma N-p-tau181 levels increased in the early stage
20 even when MMSE scores were within the normal range, and its increase slowed down
21 in the later phase when cognitive impairment advanced. In support of these findings, the
22 elevation of CSF p-tau181 measured with an immunoassay targeting the mid-portion of
23 tau protein occurred later than CSF N-p-tau181,⁴⁹ as observed in our plasma assay.
24 However, the increase in CSF N-p-tau181 species ceased and decreased after neuronal
25 dysfunction started in the familial AD cohort.⁵⁶ In light of these current and previous
26 findings, plasma mid-p-tau181 serves as a biomarker to monitor the disease progression
27 over a phase characterized by fibrillar tau deposition and consequent neurodegeneration
28 and cognitive declines, whereas N-p-tau levels indicate earlier pathologies primarily
29 induced by A β accumulations.

30 The PSP group also showed a significant elevation in plasma mid-p-tau181,
31 deviating from the results of the N-p-tau assay and leading to a slight decrease in
32 specificity to AD. Phosphorylation in the mid-region has also been observed in non-AD
33 tauopathies, such as PSP,⁵⁷ with some previous studies reporting that soluble mid-p-tau
34 levels in CSF might be elevated in non-AD tauopathies.^{58,59} However, plasma mid-p-
35 tau181 levels were not correlated with tau PET accumulation in the PSP patients
36 (Supplementary Figure 8). Accordingly, the underlying pathophysiological basis for the

1 observed increase in plasma mid-p-tau181 levels in our PSP group remains elusive.

2 This study has several limitations worth noting. Firstly, our sample size was
3 modest, and longitudinal data were lacking. As such, clinical cohort studies assessing
4 neuroimaging- and fluid-based biomarkers with a larger scale are required to justify the
5 present findings and are underway. Secondly, it is yet to be examined whether plasma
6 mid-p-tau181 correlates with measures of tau PET with other tracers, including ¹⁸F-
7 flortaucipir and ¹⁸F-MK6240, in the AD spectrum. ¹⁸F-florzolotau and these tracers
8 yield similar cortical and limbic maps of AD-type tau aggregates,⁵⁹ while there might be
9 diversity of the compound reactivity with various tau fibril subtypes. Moreover, distinct
10 significances of tau phosphorylation at different sites may need to be taken into account,
11 as a few of the amino acid residues can be phosphorylated at an incipient stage of AD
12 pathology, followed by other epitopes.^{56,60} In addition, previous reports indicated a
13 moderate correlation between plasma p-tau217 and postmortem or PET-detectable tau
14 pathologies in the AD brain,^{18,19,32} and it is accordingly intriguing to compare the
15 performances of mid-p-tau assays targeting phosphorylation sites other than Thr181.

16 To conclude, the present multimodal bioanalysis of AD-spectrum and control
17 cohort subjects has demonstrated the capability of the newly developed plasma mid-p-
18 tau181 assay for pursuing the dynamics of tau fragments in association with the tangle
19 formation and for the biological staging of AD. Although tau fragments in the CSF have
20 been measured and shown to correlate with tau pathologies,^{61,62} there are still unmet
21 needs for implementing comprehensively validated blood-based biomarkers that
22 accurately reflect cerebral tau burden with minimal interference by amyloid deposition.
23 Our novel mid-p-tau assay potentially offers a biomarker with high accessibility and
24 functionality for evaluating the evolution of neurodegenerative tau pathogenesis that has
25 been investigated only by PET. Notwithstanding the necessity for additional proofs, this
26 technology will also be applicable to the selection of patients most suitable for anti-A β
27 DMTs and the examining efficacies of tau-targeted therapies.

28 29 **Methods**

30 ***Participants***

31 We recruited a cohort of 186 individuals comprising 43 CN individuals, 30 patients with
32 MCI due to AD, 31 patients with dementia due to AD, 52 patients with PSP, and 30
33 patients with other FTLD syndromes between January 2018 and September 2022. The
34 other FTLDs comprised 12 cases with corticobasal syndrome (CBS), 10 cases with
35 behavioral-variant frontotemporal dementia (BvFTD), 7 cases with frontotemporal
36 dementia and parkinsonism linked to chromosome 17 MAPT (FTDP-17/MAPT), and 1

1 case of primary progressive aphasia. CN individuals were those aged older than 40
2 years who had no history of neurological and psychiatric disorders, had a MMSE score
3 of ≥ 28 , or had a Montreal Cognitive Assessment score of ≥ 26 and Geriatric Depression
4 Scale score of ≤ 5 .³⁵ Patients with MCI and dementia due to AD underwent clinical
5 evaluations. Cognitive impairment severity was defined as MMSE < 24 and CDR ≥ 1
6 for dementia and MMSE ≥ 26 and CDR = 0.5 for MCI.³⁵ Patients with PSP and other
7 FTLD syndromes were diagnosed according to established criteria previously
8 reported.^{34,35}

9 In the present study, the diagnosis of patients with MCI and dementia due to AD
10 required brain amyloid positivity in PET scans, and they were combined and
11 categorized into the AD group based on the concept of the AD continuum. We excluded
12 patients with PSP and other FTLD who had positive amyloid PET results to eliminate
13 the influence of mixed pathology. Those with other FTLDs were heterogeneous and
14 categorized into the FTLD group. Furthermore, CN individuals with a positive result on
15 either or both amyloid and tau PET scans were also excluded as they were considered to
16 have been in the preclinical AD stage. Amyloid positivity was defined based on ¹¹C-
17 PiB-PET visual inspection performed by a minimum of three specialists with expertise
18 in the field.³⁴ Tau PET negativity in CN individuals was defined according to the AD
19 tau score (< 0.1986) and PSP tau score (< 0.3431) as reported previously.³⁵ These
20 scores, which were calculated from ¹⁸F-florzorotau PET images via our established
21 machine learning algorithm, possess a high degree of sensitivity and specificity in
22 discriminating CN individuals from patients with AD and PSP.³⁵ Consequently, after
23 excluding 3 CN individuals and 11 MCI, 2 AD, 2 PSP, and 4 FTLD patients according
24 to the aforementioned criteria, our final cohort consisted of 164 participants comprising
25 40 CN individuals and 48 AD, 50 PSP, and 26 FTLD patients.

26 This study was approved by the National Institutes for Quantum Science and
27 Technology Certified Review Board. Written informed consent was obtained from all
28 participants and spouses or close family members when participants were cognitively
29 impaired. This study was registered with the UMIN Clinical Trial Registry (UMIN-
30 CRT; number 000041383).

31

32 ***Blood sampling***

33 We obtained blood samples through venous puncture on the same day as the PET scan.
34 A total of 8 mL of blood was collected in ethylenediaminetetraacetic acid (EDTA)-
35 containing tubes. After collection, plasma was separated by centrifugation for 10 min at
36 2000g, aliquoted into polypropylene tubes, and then stored at -80°C until analysis.

1

2 ***Measurements of blood biomarkers***

3 We developed a novel immunoassay able to quantify plasma levels of both N- and C-
4 terminally truncated p-tau181 fragments run on a highly sensitive automated digital
5 ELISA platform (Simoa HD-X Analyzer, Quanterix, Lexington, KY, USA) and
6 measured the levels of p-tau181 including such fragments in human plasma. The details
7 of the procedures for method validation of this original immunoassay are described in
8 the Supplementary Methods and Results. We also quantified plasma levels of the A/T/N
9 biomarkers⁷ (A β 42, A β 40, p-tau181, and NfL instead of total tau in the original paper)
10 utilizing the Simoa platform (Quanterix) equipped with validated assay kits. Procedures
11 were performed following the manufacturer's instructions. This study employed the
12 A β 42/A β 40 ratio as a proxy for cerebral amyloid burden. Plasma p-tau181 measured
13 using the commercial kit (Simoa pTau-181 V2.1 Assay, Quanterix) was defined as N-p-
14 tau181, whereas plasma p-tau181 measured using the originally developed
15 immunoassay run on the Simoa system was defined as mid-p-tau181.

16 All plasma samples were diluted four times with the respective sample diluent
17 before the assays to minimize matrix effects. All plasma samples were run in duplicate
18 with the same lot of standards. The relative concentration estimates of plasma
19 biomarkers were calculated according to their respective standard curves.

20

21 ***PET and MRI data acquisition***

22 Amyloid and tau deposits in the brains of all participants were assessed using PET with
23 ¹¹C-PiB and ¹⁸F-florzorotau as described in other clinical trials (UMIN-CRT; number
24 000026385, 000026490, 000029608, 000030248, and 000043458). One PSP patient
25 who had already been confirmed to be A β -negative at another facility no longer
26 underwent ¹¹C-PiB-PET at our center. The scan protocol was described as follows:
27 parametric ¹¹C-PiB-PET images were acquired 50–70 min after injection (injected dose:
28 528.5 ± 65.5 MBq, molar activity 90.2 ± 26.2 GBq/ μ mol); ¹⁸F-florzorotau PET images
29 were obtained 90–110 min after injection (injected dose: 186.6 ± 7.4 MBq, molar
30 activity 244.2 ± 86.7 GBq/ μ mol). PET was primarily conducted using a Biograph mCT
31 flow system (Siemens Healthcare), with some cases using the Discovery MI (GE
32 Healthcare) (9 ¹¹C-PiB scans in CN individuals; 22 ¹¹C-PiB scans and 3 ¹⁸F-florzorotau
33 scans in AD patients; 7 ¹¹C-PiB scans in PSP patients; and 4 ¹¹C-PiB scans in FTLD
34 patients) and an ECAT EXACT HR+ scanner (CTI PET Systems, Inc.) (three ¹¹C-PiB
35 scans in CN individuals, four ¹¹C-PiB scans in AD patients, nine ¹¹C-PiB scans in PSP
36 patients, and three ¹¹C-PiB scans in FTLD patients). Acquired PET images were

1 reconstructed using the filtered back projection method with a Hanning filter. MRI
2 examination was conducted simultaneously with PET using a 3-T scanner
3 (MAGNETOM Verio; Siemens Healthcare). The anatomical images were acquired
4 using a three-dimensional T1-weighted gradient echo sequence that produced a gapless
5 series of thin sagittal sections (TE = 1.95 ms, TR = 2300 ms, TI = 900 ms, flip angle =
6 9°, acquisition matrix = 512 × 512 × 176, voxel size = 1 × 0.488 × 0.488 mm³).

7 8 ***Imaging analyses***

9 All images were preprocessed using PMOD software (version 4.3, PMOD Technologies
10 Ltd), FreeSurfer 6.0 (<http://surfer.nmr.mgh.harvard.edu/>), MATLAB (The Mathworks,
11 Natick, MA, USA), and Statistical Parametric Mapping software (SPM12, Wellcome
12 Department of Cognitive Neurology). PET images were co-registered with individual
13 anatomical T1-weighted MR images, and SUVR images were generated using each
14 reference region. The cerebellar cortex was the reference region for the ¹¹C-PiB-PET
15 images. For ¹⁸F-florzorotau PET images, an optimized reference region was set through
16 an in-house MATLAB script that considered the distribution of diverse tau lesions
17 throughout the entire gray matter and extracted optimized reference regions on an
18 individual basis.⁶³ Each PET and MR image was also normalized to the Montreal
19 Neurologic Institute space using the Diffeomorphic Anatomical Registration Through
20 Exponentiated Lie Algebra (DARTEL) algorithm and was smoothed with a Gaussian
21 kernel at 8-mm full-width at half maximum in voxel-wise analyses.

22 We performed an ROI analysis targeting AD pathologies on each imaging modality
23 to quantify the regional amyloid/tau burden and cortical thinning. The amyloid burden
24 was assessed using a Centiloid atlas (frontal, temporal, parietal, precuneus, anterior
25 striatum, and insula) implemented in the PMOD Neuro Tool (PMOD Technologies Ltd).
26 Each Centiloid SUVR was calculated and converted to a Centiloid score (CL score)⁶⁴
27 using PET data from 12 young CN individuals aged 23–43 years and 25 cases of AD
28 patients scanned at our institution. Tau burden was assessed using ROIs targeting tau
29 pathology associated with AD labeling through FreeSurfer, Braak staging ROIs (I/II,
30 III/IV, V/VI),³⁶ and temporal meta-ROI (entorhinal, amygdala, parahippocampal,
31 fusiform, inferior temporal, and middle temporal).³⁷ We excluded the hippocampus from
32 the Braak stage I/II ROI because of potential spill-in from the choroid plexus.³⁴
33 Additionally, we also estimated the AD tau score to assess AD-type tau burden in the
34 brain, which was calculated using an Elastic Net model trained on tau PET data as
35 previously reported.³⁵ A qualitative analysis based on the values obtained from these
36 ROI analyses was also conducted to evaluate the presence of tau lesions. For Braak

1 staging, the SUVR values were converted to z-values based on another young CN
2 cohort, and the highest stage was assigned based on the average regional Z-score (>2.5).
3 Those with stages 0–I/II were classified as tau-negative, whereas those with stages
4 III/IV–V/VI were classified as tau-positive. The cutoff value of temporal meta-ROI
5 SUVR was set at 1.105 to maximize the differentiation between CN individuals and AD
6 patients during ROC analysis (see Supplementary material for detailed information).
7 and the cutoff value of AD tau score was set at 0.1986 as described elsewhere.³⁵
8 Cortical thickness was measured using the cortical signature of AD through FreeSurfer
9 (medial temporal, inferior temporal, temporal pole, angular, superior frontal, superior
10 parietal, supramarginal, precuneus, and middle frontal).³⁸

11

12 ***Statistical analyses***

13 Statistical analyses were conducted using GraphPad Prism version 9 (GraphPad
14 Software) and R version 4.3.1. Initially, group comparisons were performed using the
15 Kruskal–Wallis test or Mann–Whitney U test for demographic data and measured blood
16 biomarker values and Fisher's exact test for gender ($p < 0.05$, corrected by Dunn's
17 multiple comparisons). Subsequently, correlation analyses were conducted to verify the
18 association between each p-tau181 assay and each imaging biomarker. During voxel-
19 based analyses, a linear regression model was applied using SPM12. The extent
20 threshold was established based on the expected voxels per cluster. For multiple voxel
21 comparisons, family-wise error corrections at the cluster level were applied ($p < 0.05$,
22 FWE-corrected). During ROI-based analyses, Pearson's correlation analyses were
23 performed ($p < 0.05$, corrected by Bonferroni multiple comparisons), and nonlinear
24 regression analysis (quadratic) was conducted when no significant correlation was
25 observed. Results were adopted when the nonlinear analysis based on Akaike's
26 Information Criterion (AIC) showed a better fit than the linear one. Besides, we also
27 incorporated a multiple linear regression analysis to explore the relationships between
28 amyloid, tau, and each plasma pTau level. In addition, ability of each blood biomarker
29 to discriminate between the presence or absence of AD pathology, as defined by
30 amyloid or tau PET positivity, was also evaluated by calculating AUC values from ROC
31 curve analyses. The Youden index maximizing sensitivity plus specificity minus one
32 determined the optimized cutoff value. Finally, to explore the trajectories from CN to
33 AD for each blood/imaging biomarker, we converted each biomarker value to a z-value
34 based on CN data. Thereafter, we examined their relationship with cognitive
35 dysfunction (MMSE score). A linear or sigmoidal 4PL regression analysis was adapted,
36 and the better-fitting model was selected based on AIC.

1

2 **Data availability**

3 The data supporting this study's findings are available from the corresponding author on
4 reasonable request. Sharing and reuse of data require the expressed written permission
5 of the authors, as well as clearance from the Institutional Review Boards.

6

7 **References**

- 8 1. Nichols, E. *et al.* Estimation of the global prevalence of dementia in 2019 and
9 forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study
10 2019. *The Lancet Public Health* **7**, e105–e125 (2022).
- 11 2. Cummings, J. *et al.* Alzheimer's disease drug development pipeline: 2022.
12 *Alzheimers Dement. (N. Y.)* **8**, e12295 (2022).
- 13 3. EMERGE and EMERGE and ENGAGE Topline Results: Two Phase 3 Studies to
14 Evaluate Aducanumab in Patients With Early Alzheimer's Disease
15 ([https://investors.biogen.com/static-files/ddd45672-9c7e-4c99-8a06-](https://investors.biogen.com/static-files/ddd45672-9c7e-4c99-8a06-3b557697c06f)
16 [3b557697c06f](https://investors.biogen.com/static-files/ddd45672-9c7e-4c99-8a06-3b557697c06f)). 2019.
- 17 4. Sims, J. R. *et al.* Donanemab in early symptomatic Alzheimer disease: The
18 TRAILBLAZER-ALZ 2 randomized clinical trial. *JAMA* **330**, 512–527 (2023).
- 19 5. van Dyck, C. H. *et al.* Lecanemab in early Alzheimer's disease. *N. Engl. J. Med.*
20 **388**, 9–21 (2023).
- 21 6. Imbimbo, B. P., Ippati, S., Watling, M. & Balducci, C. A critical appraisal of tau-
22 targeting therapies for primary and secondary tauopathies. *Alzheimers. Dement.* **18**,
23 1008–1037 (2022).
- 24 7. Jack, C. R., Jr *et al.* NIA-AA Research Framework: Toward a biological definition
25 of Alzheimer's disease. *Alzheimers. Dement.* **14**, 535–562 (2018).
- 26 8. Villemagne, V. L., Doré, V., Burnham, S. C., Masters, C. L. & Rowe, C. C. Imaging
27 tau and amyloid- β proteinopathies in Alzheimer disease and other conditions. *Nat.*
28 *Rev. Neurol.* **14**, 225–236 (2018).
- 29 9. Teng, E. *et al.* Safety and efficacy of semorinemab in individuals with prodromal to
30 mild Alzheimer disease: A randomized clinical trial. *JAMA Neurol.* **79**, 758–767
31 (2022).
- 32 10. Sevigny, J. *et al.* The antibody aducanumab reduces A β plaques in Alzheimer's
33 disease. *Nature* **537**, 50–56 (2016).
- 34 11. Mintun, M. A., Wessels, A. M. & Sims, J. R. Donanemab in early Alzheimer's
35 disease. Reply. *The New England journal of medicine* vol. 385 667 (2021).
- 36 12. Karikari, T. K. *et al.* Blood phospho-tau in Alzheimer disease: analysis,

- 1 interpretation, and clinical utility. *Nat. Rev. Neurol.* **18**, 400–418 (2022).
- 2 13. Dubois, B. *et al.* Advancing research diagnostic criteria for Alzheimer’s disease: the
3 IWG-2 criteria. *Lancet Neurol.* **13**, 614–629 (2014).
- 4 14. McKhann, G. M. *et al.* The diagnosis of dementia due to Alzheimer’s disease:
5 recommendations from the National Institute on Aging-Alzheimer’s Association
6 workgroups on diagnostic guidelines for Alzheimer’s disease. *Alzheimers. Dement.*
7 **7**, 263–269 (2011).
- 8 15. Hansson, O. *et al.* The Alzheimer’s association appropriate use recommendations
9 for blood biomarkers in Alzheimer’s disease. *Alzheimers. Dement.* **18**, (2022).
- 10 16. Tatebe, H. *et al.* Quantification of plasma phosphorylated tau to use as a biomarker
11 for brain Alzheimer pathology: pilot case-control studies including patients with
12 Alzheimer’s disease and down syndrome. *Mol. Neurodegener.* **12**, 63 (2017).
- 13 17. Karikari, T. K. *et al.* Blood phosphorylated tau 181 as a biomarker for Alzheimer’s
14 disease: a diagnostic performance and prediction modelling study using data from
15 four prospective cohorts. *Lancet Neurol.* **19**, 422–433 (2020).
- 16 18. Palmqvist, S. *et al.* Discriminative accuracy of plasma phospho-tau217 for
17 Alzheimer disease vs other neurodegenerative disorders. *JAMA* **324**, 772–781
18 (2020).
- 19 19. Janelidze, S. *et al.* Associations of Plasma Phospho-Tau217 Levels With Tau
20 Positron Emission Tomography in Early Alzheimer Disease. *JAMA Neurol.* **78**,
21 149–156 (2021).
- 22 20. Fitzpatrick, A. W. P. *et al.* Cryo-EM structures of tau filaments from Alzheimer’s
23 disease. *Nature* **547**, 185–190 (2017).
- 24 21. Koss, D. J. *et al.* Soluble pre-fibrillar tau and β -amyloid species emerge in early
25 human Alzheimer’s disease and track disease progression and cognitive decline.
26 *Acta Neuropathol.* **132**, 875–895 (2016).
- 27 22. Han, P. *et al.* A Quantitative Analysis of Brain Soluble Tau and the Tau Secretion
28 Factor. *J. Neuropathol. Exp. Neurol.* **76**, 44–51 (2017).
- 29 23. Sato, C. *et al.* Tau Kinetics in Neurons and the Human Central Nervous System.
30 *Neuron* **98**, 861–864 (2018).
- 31 24. Thijssen, E. H. *et al.* Diagnostic value of plasma phosphorylated tau181 in
32 Alzheimer’s disease and frontotemporal lobar degeneration. *Nat. Med.* **26**, 387–397
33 (2020).
- 34 25. Lantero Rodriguez, J. *et al.* Plasma p-tau181 accurately predicts Alzheimer’s
35 disease pathology at least 8 years prior to post-mortem and improves the clinical
36 characterisation of cognitive decline. *Acta Neuropathol.* **140**, 267–278 (2020).

- 1 26. Karikari, T. K. *et al.* Diagnostic performance and prediction of clinical progression
2 of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.
3 *Mol. Psychiatry* **26**, 429–442 (2021).
- 4 27. Palmqvist, S. *et al.* Prediction of future Alzheimer's disease dementia using plasma
5 phospho-tau combined with other accessible measures. *Nat. Med.* **27**, 1034–1042
6 (2021).
- 7 28. Groot, C. *et al.* Phospho-tau with subthreshold tau-PET predicts increased tau
8 accumulation rates in amyloid-positive individuals. *Brain* (2022)
9 doi:10.1093/brain/awac329.
- 10 29. Mattsson-Carlsson, N. *et al.* Soluble P-tau217 reflects amyloid and tau pathology
11 and mediates the association of amyloid with tau. *EMBO Mol. Med.* **13**, e14022
12 (2021).
- 13 30. Therriault, J. *et al.* Association of Phosphorylated Tau Biomarkers With Amyloid
14 Positron Emission Tomography vs Tau Positron Emission Tomography. *JAMA*
15 *Neurol.* (2022) doi:10.1001/jamaneurol.2022.4485.
- 16 31. Smirnov, D. S. *et al.* Plasma biomarkers for Alzheimer's Disease in relation to
17 neuropathology and cognitive change. *Acta Neuropathol.* **143**, 487–503 (2022).
- 18 32. Salvadó, G. *et al.* Specific associations between plasma biomarkers and
19 postmortem amyloid plaque and tau tangle loads. *EMBO Mol. Med.* e2463 (2023).
- 20 33. Guillozet-Bongaarts, A. L. *et al.* Tau truncation during neurofibrillary tangle
21 evolution in Alzheimer's disease. *Neurobiol. Aging* **26**, 1015–1022 (2005).
- 22 34. Tagai, K. *et al.* High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer's
23 and Non-Alzheimer's Disease Tauopathies. *Neuron* **109**, 42–58.e8 (2021).
- 24 35. Endo, H. *et al.* A Machine Learning-Based Approach to Discrimination of
25 Tauopathies Using [18 F]PM-PBB3 PET Images. *Mov. Disord.* **37**, 2236–2246
26 (2022).
- 27 36. Schöll, M. *et al.* PET Imaging of Tau Deposition in the Aging Human Brain.
28 *Neuron* **89**, 971–982 (2016).
- 29 37. Ossenkoppele, R. *et al.* Discriminative Accuracy of [18F]flortaucipir Positron
30 Emission Tomography for Alzheimer Disease vs Other Neurodegenerative
31 Disorders. *JAMA* **320**, 1151–1162 (2018).
- 32 38. Dickerson, B. C. *et al.* The Cortical Signature of Alzheimer's Disease: Regionally
33 Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD
34 Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals. *Cereb.*
35 *Cortex* **19**, 497–510 (2008).
- 36 39. Venkatramani, A. & Panda, D. Regulation of neuronal microtubule dynamics by

- 1 tau: Implications for tauopathies. *Int. J. Biol. Macromol.* **133**, 473–483 (2019).
- 2 40. Zhang, F. *et al.* β -amyloid redirects norepinephrine signaling to activate the
3 pathogenic GSK3 β /tau cascade. *Sci. Transl. Med.* **12**, (2020).
- 4 41. He, Z. *et al.* Amyloid- β plaques enhance Alzheimer's brain tau-seeded pathologies
5 by facilitating neuritic plaque tau aggregation. *Nat. Med.* **24**, 29–38 (2018).
- 6 42. Maia, L. F. *et al.* Changes in amyloid- β and Tau in the cerebrospinal fluid of
7 transgenic mice overexpressing amyloid precursor protein. *Sci. Transl. Med.* **5**,
8 194re2 (2013).
- 9 43. Karikari, T. K. *et al.* Diagnostic performance and prediction of clinical progression
10 of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.
11 *bioRxiv* (2020) doi:10.1101/2020.07.15.20154237.
- 12 44. Thijssen, E. H. *et al.* Plasma phosphorylated tau 217 and phosphorylated tau 181 as
13 biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a
14 retrospective diagnostic performance study. *Lancet Neurol.* **20**, 739–752 (2021).
- 15 45. Benussi, A. *et al.* Classification accuracy of blood-based and neurophysiological
16 markers in the differential diagnosis of Alzheimer's disease and frontotemporal
17 lobar degeneration. *Alzheimers. Res. Ther.* **14**, 155 (2022).
- 18 46. Mielke, M. M. *et al.* Comparison of Plasma Phosphorylated Tau Species With
19 Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular
20 Pathology, and Cognitive Outcomes. *JAMA Neurol.* **78**, 1108–1117 (2021).
- 21 47. Janelidze, S. *et al.* Head-to-head comparison of 10 plasma phospho-tau assays in
22 prodromal Alzheimer's disease. *Brain* (2022) doi:10.1093/brain/awac333.
- 23 48. Milà-Alomà, M. *et al.* Plasma p-tau231 and p-tau217 as state markers of amyloid- β
24 pathology in preclinical Alzheimer's disease. *Nat. Med.* **28**, 1797–1801 (2022).
- 25 49. Suárez-Calvet, M. *et al.* Novel tau biomarkers phosphorylated at T181, T217 or
26 T231 rise in the initial stages of the preclinical Alzheimer's continuum when only
27 subtle changes in A β pathology are detected. *EMBO Mol. Med.* **12**, e12921 (2020).
- 28 50. Dujardin, S. *et al.* Tau molecular diversity contributes to clinical heterogeneity in
29 Alzheimer's disease. *Nat. Med.* **26**, 1256–1263 (2020).
- 30 51. García-Sierra, F., Ghoshal, N., Quinn, B., Berry, R. W. & Binder, L. I.
31 Conformational changes and truncation of tau protein during tangle evolution in
32 Alzheimer's disease. *J. Alzheimers. Dis.* **5**, 65–77 (2003).
- 33 52. Bondareff, W. *et al.* Molecular analysis of neurofibrillary degeneration in
34 Alzheimer's disease. An immunohistochemical study. *Am. J. Pathol.* **137**, 711–723
35 (1990).
- 36 53. Horowitz, P. M. *et al.* Early N-terminal changes and caspase-6 cleavage of tau in

- 1 Alzheimer's disease. *J. Neurosci.* **24**, 7895–7902 (2004).
- 2 54. Bloom, G. S. Amyloid- β and tau: the trigger and bullet in Alzheimer disease
3 pathogenesis. *JAMA Neurol.* **71**, 505–508 (2014).
- 4 55. Cai, Y. *et al.* Initial levels of β -amyloid and tau deposition have distinct effects on
5 longitudinal tau accumulation in Alzheimer's disease. *Alzheimers. Res. Ther.* **15**, 30
6 (2023).
- 7 56. Barthélemy, N. R. *et al.* A soluble phosphorylated tau signature links tau, amyloid
8 and the evolution of stages of dominantly inherited Alzheimer's disease. *Nat. Med.*
9 **26**, 398–407 (2020).
- 10 57. Kametani, F. *et al.* Comparison of Common and Disease-Specific Post-translational
11 Modifications of Pathological Tau Associated With a Wide Range of Tauopathies.
12 *Front. Neurosci.* **14**, 581936 (2020).
- 13 58. Kurihara, M. *et al.* CSF P-Tau181 and Other Biomarkers in Patients With Neuronal
14 Intranuclear Inclusion Disease. *Neurology* **100**, e1009–e1019 (2023).
- 15 59. Villemagne, V. L. *et al.* CenTauR: Toward a universal scale and masks for
16 standardizing tau imaging studies. *Alzheimers. Dement.* **15**, e12454 (2023).
- 17 60. Barthélemy, N. R. *et al.* Cerebrospinal fluid phospho-tau T217 outperforms T181 as
18 a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-
19 positive patient identification. *Alzheimers. Res. Ther.* **12**, 26 (2020).
- 20 61. Blennow, K. *et al.* Cerebrospinal fluid tau fragment correlates with tau PET: a
21 candidate biomarker for tangle pathology. *Brain* **143**, 650–660 (2020).
- 22 62. Horie, K. *et al.* CSF MTBR-tau243 is a specific biomarker of tau tangle pathology
23 in Alzheimer's disease. *Nat. Med.* **29**, 1954–1963 (2023).
- 24 63. Tagai, K. *et al.* An optimized reference tissue method for quantification of tau
25 protein depositions in diverse neurodegenerative disorders by PET with 18F-PM-
26 PBB3 (18F-APN-1607). *Neuroimage* **264**, 119763 (2022).
- 27 64. Klunk, W. E. *et al.* The Centiloid Project: Standardizing quantitative amyloid
28 plaque estimation by PET. *Alzheimers. Dement.* **11**, 1 (2015).

30 **Funding**

31 This study was supported in part by AMED under Grant Numbers
32 JP18dm0207018, JP19dm0207072, JP18dk0207026, JP19dk0207049,
33 21wm0425015h0001, and 20356533; MEXT KAKENHI under Grant Numbers
34 JP16H05324 and JP18K07543; JST under Grant Numbers JPMJCR1652 and
35 JPMJMS2024; and the Kao Research Council for the Study of Healthcare Science,
36 Biogen Idec Inc. and APRINOIA Therapeutics.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

Acknowledgements

The authors thank all patients and their caregivers for participation in this study, as well as clinical research coordinators, PET and MRI operators, radiochemists, and research ethics advisers at QST for their assistance with the current projects. We thank APRINOIA Therapeutics for kindly sharing a precursor of ¹⁸F-florzorotau. The authors acknowledge support with the recruitment of patients by Shunichiro Shinagawa at the Department of Psychiatry, Jikei University School of Medicine; Shigeki Hirano at the Department of Neurology, Chiba University; Taku Hatano, Yumiko Motoi, and Shinji Saiki at the Department of Neurology, Juntendo University School of Medicine; Ikuko Aiba at the Department of Neurology, National Hospital Organization Higashinagoya National Hospital; Yasushi Shiio and Tomonari Seki at the Department of Neurology, Tokyo Teishin Hospital; Hisaomi Suzuki at the National Hospital Organization Shimofusa Psychiatric Medical Center.

Author contributions

Kenji Tagai, Harutsugu Tatebe: Conceptualization, Methodology, Formal analysis, Writing - original draft. **Sayo Matsuura, Zhang Hong:** Measurement of samples. **Naomi Kokubo, Kiwamu Matsuoka, Hironobu Endo, Asaka Oyama, Kosei Hirata, Hitoshi Shinotoh, Yuko Kataoka, Hideki Matsumoto, Masaki Oya, Shin Kurose, Keisuke Takahata, Masanori Ichihashi, Manabu Kubota, Chie Seki, Hitoshi Shimada, Yuhei Takado:** Collection of clinical data. **Kazunori Kawamura, Ming-Rong Zhang:** Radioligand synthesis. **Yoshiyuki Soeda, Akihiko Takashima:** Assay validation. **Makoto Higuchi, Takahiko Tokuda:** Conceptualization, Writing - review & editing, Funding acquisition, Supervision

Competing interests

Hitoshi Shimada, Ming-Rong Zhang, and Makoto Higuchi hold patents on compounds related to the present report (JP 5422782/EP 12 884 742.3/CA2894994/HK1208672).

1 **Table 1.** Demographic and blood biomarker data of the participants.

2

	CN	AD	PSP	FTLD
Demographics				
Number	40	48	50	26
Age	66.0 (10.4)	69.3 (11.4)	71.2 (7.5)	65.0 (11.4)
Gender (male/female)	21/19	27/21	21/29	18/8
Years of schooling	14.8 (1.6)	13.9 (2.2)	13.6 (2.6)	14.0 (2.8)
MMSE	29.3 (1.0) †	21.9 (4.1) *	24.8 (5.8) *†	23.8 (6.1) *
FAB	16.7 (1.2) †	13.0 (3.0) *	12.0 (3.6) *	11.0 (4.8) *
CDR (0.5/1/2/3)	N/A	23/20/4/1	N/A	N/A
PSPRS	N/A	N/A	38.1 (18.2)	N/A
Blood biomarkers				
A β 42/40	0.093 (0.020) †	0.067 (0.020) †	0.096 (0.048) †	0.089 (0.022) †
N-p-tau181 (pg/mL)	1.82 (0.79) †	4.07 (1.52) *	2.27 (1.06) †	2.25 (1.25) †
mid-p-tau181 (pg/mL)	0.83 (0.65) †	2.30 (1.31) *	1.56 (0.91) *	0.96 (0.63) †
NfL (pg/mL)	19.5 (12.5) †‡	33.2 (21.3) *‡	58.3 (39.7) *†	51.8 (39.3) *

3 CN, cognitively normal; AD, Alzheimer's disease; PSP, progressive supranuclear palsy;
4 FTLD, frontotemporal degeneration; MMSE, Mini-Mental State Examination; FAB,
5 Frontal Assessment Battery; CDR, Clinical Dementia Rating scale; PSPRS, progressive
6 supranuclear palsy rating scale; N/A, not applicable; A β , amyloid beta; N-p-tau181,
7 phosphorylated tau181 measured using the commercial kit directed to the C-terminally
8 truncated N-terminal fragment of p-tau (Simoa pTau-181 V2.1 Assay, Quanterix); mid-
9 p-tau181, phosphorylated tau181 measured using the originally developed immunoassay
10 directed to both the N- and C-terminally truncated p-tau181 fragments; NfL,
11 neurofilament light chain.

12 Values are presented as mean \pm standard deviation.

13 *, Significant difference between CN, †, between AD, ‡, between PSP, $P < 0.05$
14 (corrected by Dunn's multiple comparisons)

15

1 **Table 2.** Performance of mid-p-tau181 in discriminating tau PET status determined
2 using three different methods of evaluating brain tau burden on tau PET in the
3 cognitively normal and AD continuum subjects

4

	Sensitivity (%)	Specificity (%)	Cutoff value (pg/mL)	AUC
Braak staging	62.8	92.5	1.76	0.859
Temporal meta SUVR	71.8	88.6	1.69	0.855
AD tau score	70.5	88.1	1.62	0.870

5

6 All parameters were estimated from receiver operating characteristic curve analyses. We
7 set each cutoff value according to Youden index obtained in the respective receiver
8 operating characteristic analyses.

9 SUVR, standardized uptake value ratio; AUC, area under the receiver operating
10 characteristic curve.

11

12

1 **Figure legends**

2

3 **Figure 1. Correlations between plasma mid-p-tau levels and tau PET results in the**
4 **subjects with AD continuum.**

5 (A) The correlation between plasma mid-p-tau181 levels and ¹⁸F-florzorotau tau PET is
6 depicted through its topographical representation (p < 0.05, family-wise error
7 corrected).

8 (B, C) The correlation between plasma mid-p-tau181 levels and tau PET tracer
9 accumulation in each ROI is portrayed via scatter plots. Pearson's correlation analysis
10 was employed to calculate the r and p values. Statistical significance was established at
11 p < 0.0125, corrected for multiple comparisons using the Bonferroni method based on
12 the number of ROIs. Regression analysis, indicated by a straight or curved line, depicts
13 the preferred model, with its goodness of fit quantified using the R² value.

14 SUVR, standardized uptake value ratio; AD tau score, a machine learning-based
15 measure indicating AD-related features in tau PET images.

16 Mid-p-tau181, phosphorylated tau181 measured using the originally developed
17 immunoassay directed to both N- and C-terminally truncated p-tau181 fragments.

18

19 **Figure 2 Correlation between plasma N-p-tau levels measured using a conventional**
20 **p-tau assay and tau PET results in the subjects with AD continuum.**

21 (A) The correlation between plasma N-p-tau181 levels and tau PET results is
22 demonstrated through its topographical representation (p < 0.05, uncorrected).

23 (B, C) The correlation between plasma N-p-tau181 levels and tau PET tracer
24 accumulation in each ROI is depicted via scatter plots. Pearson's correlation analysis
25 was utilized to calculate the r and p values. The preferred model, indicated by regression
26 analysis, is depicted by a straight or curved line, with its goodness of fit quantified using
27 the R² value.

28 SUVR, standardized uptake value ratio; AD tau score, a machine learning-based measure
29 indicating AD-related features in tau PET images.

30 N-p-tau181, phosphorylated tau181 measured using the Simoa pTau-181 V2.1 Assay kit
31 (Quanterix).

32

33 **Figure 3 Comparative assessment of Mid-p-tau and N-p-tau levels with amyloid**
34 **and tau PET within the cognitively normal and AD continuum subjects**

35 (A) The correlation between each plasma p-tau181 level and amyloid and tau PET results
36 in a cohort with CN and AD continuum is demonstrated through its topographical

1 representation ($p < 0.05$, family-wise error corrected). Upper two rows: associations
2 between mid-p-tau and amyloid-PET (left column) and tau-PET (right column);
3 Lower two rows: associations between N-p-tau and amyloid-PET (left column) and
4 tau-PET(right column).

5 (B) The bar graphs illustrate beta coefficient values of amyloid and tau PET in multiple
6 liner regression analysis with each p-tau assay. Statistically significant differences are
7 denoted as follows: $p < 0.0005$ (****), $p < 0.005$ (**), $p < 0.05$ (*). P-values were
8 corrected for multiple comparisons using Bonferonni correction with the number of
9 explanatory variables.

10
11 **Figure 4. Correlations between plasma mid-p-tau and N-p-tau levels and MRI**
12 **structural images in the subjects with AD continuum.**

13 (A) The correlation between p-tau181 measured using the mid-p-tau181 or N-p-tau
14 assay and brain atrophy is depicted through its topographical representation ($p < 0.05$,
15 uncorrected).

16 (B) The correlation between plasma mid-p-tau181 and N-p-tau levels measured using
17 each assay and the thinning of the AD cortical signature is demonstrated via scatter
18 plots. Pearson's correlation analysis was utilized to calculate.

19 N-p-tau181, phosphorylated tau181 measured using the Simoa pTau-181 V2.1 Assay kit
20 (Quanterix); mid-p-tau181, phosphorylated tau181 measured using the originally
21 developed immunoassay directed to both N- and C-terminally truncated p-tau181
22 fragments.

23
24 **Figure 5. Scatter plots and ROC curves of the mid-p-tau181 showing its ability to**
25 **discriminate between tau PET statuses determined by three different approaches**
26 **in the cognitively normal and AD continuum subjects.**

27 Scatterplots (A) and ROC curves (B) illustrating the relationship between mid-p-tau181
28 levels and positive/negative tau PET results as determined by three different methods. In
29 the scatterplot, CN subjects are represented in purple, whereas AD continuum patients
30 are depicted in blue. The dotted line represents the mid-p-tau181 cutoff calculated based
31 on each approach. $p < 0.0001$ (****), as assessed by Mann–Whitney U test.

32
33 **Figure 6. Trajectories of the imaging and plasma A/T/N biomarkers along with the**
34 **decline in the MMSE scores.**

35 Trajectories of the changes in imaging (A) and blood-based (B) A/T/N biomarkers with
36 the decline in MMSE scores. The relationship between MMSE scores of the CN and AD

1 continuum subjects and the z-scores of each biomarker is presented as a regression line
2 that is either straight or sigmoidal, with the best fitting model being selected. The
3 biomarkers were distinguished using red, green, and blue for both imaging and blood-
4 based biomarkers, whereas N-p-tau181 was presented separately in purple. The dotted
5 line indicates z-score = 1.

6

7

8

9

Figure 1

Tau PET vs Plasma mid-p-tau181






Figure 2

Tau PET vs Plasma N-p-tau181








Figure 3

(A) Plasma mid-p-tau181



(B) Plasma mid-p-tau181



Plasma N-p-tau181




Figure 4






Figure 5





Figure 6

